Axatilimab

Axatilimab Overview

Axatilimab (specifically designated as axatilimab-csfr) is a recombinant, humanized immunoglobulin G4 (IgG4) kappa monoclonal antibody directed against the macrophage colony-stimulating factor 1 receptor (CSF-1R). Chemically, it belongs to the class of amino acids, peptides, and proteins (specifically monoclonal antibody globulins) within the organic acids superclass. It is manufactured using Chinese hamster ovary (CHO) cell suspension culture technology.

In clinical hematology, stem cell transplantation, and neuro-immunology, Axatilimab functions as a targeted immunosuppressive and anti-fibrotic agent. Formulated as a sterile, preservative-free solution for intravenous infusion (50 mg/mL, marketed under the brand name Niktimvo by Incyte Corporation and Syndax Pharmaceuticals), it is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.

What Is Axatilimab and How Does It Work?

Axatilimab acts primarily through high-affinity competitive blockade of the CSF-1R tyrosine kinase receptor.

Its primary physiological, cellular, and immunological mechanisms include:

• Targeting the CSF-1R Signaling Pathway: Colony-stimulating factor 1 receptor (CSF-1R, also known as CD115 or M-CSFR) is a cell-surface receptor tyrosine kinase expressed on monocytes, tissue-resident macrophages, and dendritic cells. Binding of its native ligands colony-stimulating factor 1 (CSF-1) and interleukin-34 (IL-34) drives monocyte differentiation, tissue macrophage survival, proliferation, and activation.
• Depletion of Pathogenic Monocytes and Macrophages: Axatilimab binds with high affinity to CSF-1R, blocking ligand binding and receptor autophosphorylation. This deprives monocyte and macrophage populations of essential survival signals, significantly reducing circulating classical/non-classical pro-inflammatory monocytes and tissue-resident pathogenic macrophages.

Is Axatilimab FDA Approved?

Yes, Axatilimab-csfr (Niktimvo) was approved by the US FDA in August 2024 for the treatment of chronic graft-versus-host disease (cGVHD) in adult and pediatric patients weighing at least 40 kg who have failed at least two prior lines of systemic therapy.

What Is Axatilimab Used For?

• Treatment of steroid-refractory or multi-agent refractory chronic graft-versus-host disease (cGVHD) in adult and pediatric patients (weighing 40 kg or more) who have previously received at least two prior lines of systemic therapy (e.g., corticosteroids, ruxolitinib, ibrutinib, or belumosudil).
• Clinical investigation in additional monocyte/macrophage-driven fibrotic and inflammatory conditions, including idiopathic pulmonary fibrosis (IPF) and periductal pancreatic neoplasms.

Before Receiving Axatilimab: Warnings & Precautions

Screen for active systemic infections and baseline hepatic dysfunction prior to treatment. Strictly contraindicated in patients with documented severe hypersensitivity to axatilimab-csfr or its excipients. Monitor for severe infusion-related reactions and dose-dependent elevations in liver and muscle enzymes (AST, ALT, CK, LDH). Avoid live or live-attenuated vaccines during therapy, and enforce effective contraception during treatment and for 30 days post-dose due to potential fetal harm.

Clinical Safety Warnings

Axatilimab carries important clinical safety warnings regarding Infusion-Related Reactions, Hepatic Enzyme Elevations & Toxicity, and Risk of Infection:

• Infusion-Related Reactions (IRRs): IRRs occur frequently during or immediately following Axatilimab infusions. Symptoms include fever, chills, rash, pruritus, dyspnea, chest discomfort, and flushing. Pre-medication with antihistamines and antipyretics is required.
• Laboratory Elevations in Liver & Muscle Enzymes: Axatilimab routinely causes transient, dose-dependent elevations in serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), creatine kinase (CK), and lipase. Monitor baseline and bi-weekly liver and muscle enzyme levels.
• Increased Infection Susceptibility: Monocyte and macrophage depletion increases susceptibility to viral, bacterial, and fungal infections. Pre-existing active infections must be treated prior to initiating therapy.

Immunizations & Vaccines

Administer all age-appropriate live or live-attenuated vaccines prior to initiating Axatilimab therapy. Live or live-attenuated vaccines are NOT recommended during treatment with Axatilimab due to potential risks of vaccine-derived infection in immunosuppressed post-transplant populations.

Who Should Not Receive Axatilimab?

• Individuals with a documented severe hypersensitivity (anaphylaxis) to Axatilimab-csfr or any formulation excipients (citric acid, sodium citrate, glycine, sucrose, polysorbate 80).
• Patients with active, severe, unmanaged systemic infections.

Axatilimab, Pregnancy & Lactation

Axatilimab is a humanized IgG4 monoclonal antibody that crosses the placental barrier, particularly during the second and third trimesters. Based on its mechanism of action (depleting macrophages necessary for tissue development), Axatilimab can cause fetal harm when administered to pregnant women. Females of reproductive potential must verify negative pregnancy status prior to initiating therapy and use effective contraception during treatment and for at least 30 days after the final dose. It is unknown whether Axatilimab passes into human breast milk; breastfeeding is not recommended during therapy and for 30 days post-dose.

Tell Your Doctor Before Receiving Axatilimab

Inform your transplant specialist or physician if you have an active infection, a history of liver disease, elevated liver enzymes, severe lung disease, or known drug allergies.

Axatilimab Dosage & Administration

Administer 0.3 mg/kg (based on actual body weight) as an intravenous infusion over 30 minutes every 2 weeks until disease progression or unacceptable toxicity. Indicated strictly for patients weighing at least 40 kg who have failed at least two prior lines of systemic therapy. Administer mandatory pre-medications 30 to 60 minutes prior to every infusion.

Standard Weight-Based Dosing Schedule

Axatilimab is administered as an intravenous infusion every 2 weeks:

• Recommended Dose (Adults and Pediatrics Weighing 40 kg or More): 0.3 mg/kg (based on actual body weight) administered as an intravenous infusion over 30 minutes every 2 weeks until disease progression or unacceptable toxicity.
• Pre-Medication Protocol: Administer pre-medication 30 to 60 minutes prior to each infusion:

• An H1-antihistamine (e.g., diphenhydramine 25 mg to 50 mg IV/oral).
• An antipyretic (e.g., acetaminophen 650 mg oral).
• Consider an H2-antagonist or systemic corticosteroid if the patient experienced prior IRRs.

Dose Adjustments for Adverse Reactions

• Infusion-Related Reactions: For Grade 1 or 2 IRRs, slow or pause the infusion rate. For Grade 3 or 4 IRRs, permanently discontinue Axatilimab.
• Transaminase Elevations (ALT/AST > 5x ULN): Withhold Axatilimab until ALT/AST recovers to less than 3x ULN, then resume at 0.3 mg/kg every 2 weeks or reduce frequency to every 4 weeks based on severity.

How Axatilimab Is Administered

• Administered strictly via intravenous infusion over 30 minutes after dilution in 0.9% Sodium Chloride Injection or 5% Dextrose Injection. Do NOT administer as an IV push or bolus.
• Infuse through a dedicated IV line containing a sterile, non-pyrogenic, low-protein-binding in-line filter (0.2 or 0.22 micron).

Axatilimab Clinical Efficacy & Research

The FDA approval of Axatilimab was established in the pivotal, randomized, open-label, dose-ranging Phase 2 AGAVE-201 trial (NCT04710537) in 241 adult and pediatric patients with recurrent or refractory cGVHD following at least two prior lines of systemic therapy. Patients treated with Axatilimab at the approved 0.3 mg/kg every 2 weeks dose achieved an Overall Response Rate (ORR) of 74% within the first 6 cycles, with a median time to initial response of 1.7 months.

Axatilimab Side Effects & Safety Profile

Binds colony-stimulating factor 1 receptor (CSF-1R), depleting pro-inflammatory monocytes and tissue-resident M2-like macrophages to halt macrophage-driven fibrosis in cGVHD target organs. Common side effects include elevated AST, ALT, LDH, CK, and lipase, as well as infusion reactions, fatigue, musculoskeletal pain, periorbital edema, and nausea. Serious risks include Grade 3 or 4 hepatotoxicity, severe infusion-related reactions, and opportunistic bacterial, viral, or fungal infections.

Common Side Effects

• Laboratory Abnormalities: Increased AST, ALT, lactate dehydrogenase (LDH), creatine kinase (CK), lipase, and amylase; decreased calcium and phosphate.
• Systemic / Local: Infusion-related reactions, fatigue, musculoskeletal pain, pyrexia, and peripheral edema.
• Gastrointestinal: Nausea, diarrhea, abdominal pain, and stomatitis.

Serious Adverse Events

• Severe Infusion-Related Reactions: Anaphylactic shock, severe bronchospasm, hypoxia, hypotension, and generalized urticaria.
• Severe Infections: Serious viral (e.g., CMV reactivation), bacterial, or fungal sepsis secondary to immune cell alterations and prior heavy immunosuppression.
• Severe Hepatotoxicity: Grade 3 or 4 transaminase elevations requiring dose modification or treatment interruption.

Managing Side Effects

Administer mandatory pre-medications prior to each infusion. Monitor complete blood counts, liver enzymes (ALT, AST, bilirubin), CK, and lipase prior to each dose. Manage periorbital edema with conservative monitoring or mild diuretics.

Axatilimab Drug Interactions & What to Avoid

Avoid live or live-attenuated vaccines during treatment due to immunosuppression and risks of vaccine-derived infection. Exercise caution when combining with other known hepatotoxic agents, as co-administration can exacerbate ALT/AST elevations. While background immunosuppressants are often continued, combining multiple agents increases overall infection risks.

Drug-Drug Interactions

• Systemic Immunosuppressants (e.g., Calcineurin Inhibitors, Corticosteroids, Jakinibs): Axatilimab is indicated for use alongside background cGVHD therapies; however, combining multiple immunosuppressants increases overall infection risks.
• Live / Live-Attenuated Vaccines: Reduced vaccine immunogenicity and potential risk of vaccine-derived infection due to immunosuppression; avoid live vaccines during therapy.

Food & Alcohol

Intravenous administration is performed in specialized post-transplant clinical settings. Food does not affect parenteral clearance. Avoid excessive alcohol to reduce additive liver enzyme strain.

Axatilimab Overdose, Emergency & Clearance

Exhibits target-mediated disposition at low doses with linear clearance at therapeutic levels (0.3 mg/kg) and an elimination half-life of 3 to 6 days. Overdose saturates CSF-1R targets, causing prolonged monocyte depletion and pronounced transaminase spikes managed via supportive care and infection surveillance. Store sterile single-dose vials refrigerated at 2°C to 8°C in original cartons protected from light; diluted IV infusion bags remain stable for 24 hours under refrigeration and must be infused within 4 hours at room temperature.

Elimination Kinetics & Clearance

Axatilimab exhibits target-mediated drug disposition (TMDD) at lower doses, reaching linear elimination kinetics as CSF-1R target receptors become saturated at the therapeutic dose of 0.3 mg/kg every 2 weeks. Following IV infusion, maximum serum concentrations (Cmax​) occur at the end of the 30-minute infusion. It distributes into vascular and extracellular fluid volumes. Because it is a humanized monoclonal antibody, it is cleared primarily via target-mediated receptor endocytosis and non-specific intracellular catabolic proteolysis.

Storage & Handling

Store sterile single-dose vials under refrigeration between 2°C and 8°C (36°F to 46°F) in original cartons to protect from direct light. Do not freeze or shake. Diluted IV infusion bags in 0.9% Sodium Chloride or 5% Dextrose should be used immediately or stored under refrigeration (2°C to 8°C) for up to 24 hours, followed by complete infusion within 4 hours of reaching room temperature. Keep strictly out of reach of children.

Patient Management & Safety Protocols

Verify patient weight (minimum 40 kg) and administer mandatory H1-antihistamine and antipyretic pre-medications prior to every infusion. Monitor complete blood counts, liver enzymes, CK, and lipase prior to each dose, and observe patients for at least 1 hour post-infusion for infusion-related reactions.

Clinical Monitoring Checklist

• Verify weight (minimum 40 kg required) and prior failure of at least two systemic cGVHD therapies.
• Screen for active bacterial, viral, or fungal infections prior to each infusion.
• Perform baseline and bi-weekly liver function tests (ALT, AST, total bilirubin), CK, LDH, and lipase.
• Administer pre-medications (antihistamine and antipyretic) 30 to 60 minutes before every infusion.
• Monitor patient during and for at least 1 hour following infusion for signs of IRRs.

Key Do’s and Don’ts

• Do administer pre-medications prior to every IV infusion.
• Do infuse over 30 minutes using a dedicated IV line with a 0.2 or 0.22-micron filter.
• Do report fever, chills, rash, dark urine, or severe joint/muscle pain immediately.
• Do not administer via rapid intravenous push or bolus.
• Do not receive live vaccines while undergoing treatment.
• Do not attempt to use in patients weighing less than 40 kg.

Frequently Asked Questions

References

• DrugBank Database – Axatilimab Profile (DB16388)
• Official FDA Prescribing Information – Niktimvo (Axatilimab-csfr Injection)

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.